BSTC - Biospecifics Technologies Corp.


Strong Growth but DecliningStock Price High


based on last 5 year data.
Income Statement is STRONG
Revenue Growth is -0.64%
Operating Income Growth is -15.02%
Net Income Growth is -17.35%
Earnings Per Share (EPS) Growth is -17.33%
Net Margin is 52.45%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 29.17
Debt Ratio is 0.03
Current Debt to Net Income Ratio is 0.0
Total Debt to Total Assets Ratio is 0.0
Cash Flow is STRONG
Cash from Operations Growth is 40.07%
Capital Expenditure is Low
Net Increase in Cash is Positive
Long Term Score Trend is NEGATIVE
Investment Risk is Moderate
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Biospecifics Technologies Corp. (BSTC) -
BioSpecifics Technologies Corp. engages in the development of an injectable collagenase clostridium histolyticum for multiple indications. It sells its products under the brand XIAFLEX. The company was founded in 1990 and is headquartered in Lynbrook, NY.
Exchange - NASDAQ
Industry - Pharmaceuticals: Major
Sector - Health Technology
CEO - Joseph Truitt
Employees - 7

Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.